BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 10023676)

  • 41. Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer.
    Gao WM; Romkes M; Day RD; Siegfried JM; Luketich JD; Mady HH; Melhem MF; Keohavong P
    Carcinogenesis; 2003 Oct; 24(10):1671-6. PubMed ID: 12844488
    [TBL] [Abstract][Full Text] [Related]  

  • 42. GSTM1, P53 and K-ras molecular detection in resectable non-small cell lung cancer by denaturing gradient gel electrophoresis-bronchoalveolar lavage fluid analysis.
    Curigliano G; Ferretti G; Mandalà M; De Pas T; Calabrò MG; Solli P; Noberasc C; de Braud F
    Anticancer Res; 2001; 21(5):3461-9. PubMed ID: 11848510
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of features of human lung cancer cell lines and their corresponding tumors.
    Wistuba II; Bryant D; Behrens C; Milchgrub S; Virmani AK; Ashfaq R; Minna JD; Gazdar AF
    Clin Cancer Res; 1999 May; 5(5):991-1000. PubMed ID: 10353731
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Carcinogen exposure, p53 alteration, and K-ras mutation in synchronous multiple primary lung carcinoma.
    Wang X; Christiani DC; Mark EJ; Nelson H; Wiencke JK; Gunn L; Wain JC; Kelsey KT
    Cancer; 1999 Apr; 85(8):1734-9. PubMed ID: 10223567
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Detection of K-ras and p53 mutations in bronchoscopically obtained malignant and non-malignant tissue from patients with non-small cell lung cancer.
    Lang SM; Stratakis DF; Freudling A; Ebelt K; Oduncu F; Hautmann H; Huber RM
    Eur J Med Res; 2000 Aug; 5(8):341-6. PubMed ID: 10958767
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer].
    Wang Y; Zhang XR; Fu J; Tan W; Zhang W
    Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):369-72. PubMed ID: 15312350
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers.
    Geradts J; Fong KM; Zimmerman PV; Maynard R; Minna JD
    Clin Cancer Res; 1999 Apr; 5(4):791-800. PubMed ID: 10213214
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer.
    Hu Y; McDermott MP; Ahrendt SA
    Clin Cancer Res; 2005 Apr; 11(7):2502-9. PubMed ID: 15814626
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer.
    Ferretti G; Curigliano G; Pastorino U; Cittadini A; Flamini G; Calabrò MG; De Pas T; Orlando L; Mandalà M; Colleoni M; Spaggiari L; Granone PL; Pagliari G; de Braud F; Fazio N; Goldhirsch A
    Clin Cancer Res; 2000 Jun; 6(6):2393-400. PubMed ID: 10873091
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
    Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
    Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic significance of p53 and Ki-67 antigen expression in surgically treated non-small cell lung cancer: immunocytochemical detection with imprint cytology.
    Maddau C; Confortini M; Bisanzi S; Janni A; Montinaro F; Paci E; Pontenani G; Rulli P; Salani A; Zappa M; Benvenuti A; Carozzi FM
    Am J Clin Pathol; 2006 Mar; 125(3):425-31. PubMed ID: 16613347
    [TBL] [Abstract][Full Text] [Related]  

  • 52. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer.
    Gallardo E; Navarro A; Viñolas N; Marrades RM; Diaz T; Gel B; Quera A; Bandres E; Garcia-Foncillas J; Ramirez J; Monzo M
    Carcinogenesis; 2009 Nov; 30(11):1903-9. PubMed ID: 19736307
    [TBL] [Abstract][Full Text] [Related]  

  • 53. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies.
    Casey G; Lopez ME; Ramos JC; Plummer SJ; Arboleda MJ; Shaughnessy M; Karlan B; Slamon DJ
    Oncogene; 1996 Nov; 13(9):1971-81. PubMed ID: 8934544
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mutations in Keap1 are a potential prognostic factor in resected non-small cell lung cancer.
    Takahashi T; Sonobe M; Menju T; Nakayama E; Mino N; Iwakiri S; Nagai S; Sato K; Miyahara R; Okubo K; Hirata T; Date H; Wada H
    J Surg Oncol; 2010 May; 101(6):500-6. PubMed ID: 20213688
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Genetic alteration of lung cancer as a prognostic marker and its therapeutic implications].
    Mitsudomi T; Takahashi T
    Gan To Kagaku Ryoho; 1997 Oct; 24 Suppl 3():345-52. PubMed ID: 9369906
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunohistochemical detection of p53 protein and prognosis of surgically resected non-small-cell lung cancer.
    Quantin X; Pujol JL; Lehmann M; Simony J; Serre I; Michel FB
    Cancer Detect Prev; 1997; 21(5):418-25. PubMed ID: 9307845
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor.
    Thorlacius S; Börresen AL; Eyfjörd JE
    Cancer Res; 1993 Apr; 53(7):1637-41. PubMed ID: 8453635
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Variation of p53 mutational spectra between carcinoma of the upper and lower respiratory tract.
    Law JC; Whiteside TL; Gollin SM; Weissfeld J; El-Ashmawy L; Srivastava S; Landreneau RJ; Johnson JT; Ferrell RE
    Clin Cancer Res; 1995 Jul; 1(7):763-8. PubMed ID: 9816043
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Correlation between RARbeta gene promoter methylation and P53 gene mutations in non-small cell lung cancer].
    Tan C; Jin YT; Xu HY; Zhang CY; Zhang H; Zhang WM; Chen CM; Sun XY
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Apr; 29(2):131-6. PubMed ID: 22487818
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The expression of O6-methylguanine DNA methyltransferase and p53 in non-small cell lung cancer and the association with the prognosis].
    Liu Y; Wang J; Zhang H; Fu XM; Wang HQ
    Zhonghua Jie He He Hu Xi Za Zhi; 2010 Jun; 33(6):427-31. PubMed ID: 20979814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.